HALOZYME THERAPEUTICS, INC. 8-K

What Happened
Halozyme Therapeutics, Inc. (HALO) filed an 8-K on May 11, 2026 (Item 2.02) to announce its financial results for the quarter ended March 31, 2026. The company furnished a press release dated May 11, 2026 as Exhibit 99.1 reporting those quarterly results. The report was signed by David Ramsay, Interim Chief Financial Officer.

Key Details

• Filing date: May 11, 2026 (8-K covering results of operations and financial condition).
• Quarterly period reported: Quarter ended March 31, 2026.
• Exhibit provided: Press release dated May 11, 2026 (Exhibit 99.1) and interactive data filed (cover page XBRL).
• Signature: 8-K executed by David Ramsay, Interim CFO.

Why It Matters
This 8-K signals that Halozyme has released its Q1 2026 earnings and related financial metrics; investors should review the attached press release (Exhibit 99.1) or the full filing on SEC EDGAR for revenue, earnings-per-share, cash position, guidance, and any management commentary. Those results can affect short-term stock movement and inform decisions about exposure to HALO, partnerships, or product-related revenue trends. To see the exact figures and management discussion, open the May 11, 2026 press release or the full 8-K (Accession No. 0001159036-26-000067) on SEC EDGAR.